Scholars Central

OtherPublished 11 Jul 2016

Potential utility of biomarkers in the diagnosis and treatment of ALS

Authors: Benjamin Chee Chuan Cheah, Steve Vucic, Matthew Colm Kiernan

Clinical Investigation

Volume 2 · Issue 1 · Pages 107–117

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Amyotrophic lateral sclerosis (ALS) is a rare, neurodegenerative disease of the human motor system, with a median survival of 3 years from symptom onset. The age of onset is typically the 5th decade, with the clinical picture representing unrelenting progressive muscle weakness and resultant disability. Despite countless clinical trials examining novel medications, disease-modifying therapies remain limited, with riluzole affording a survival benefit of approximately 3 months. To date, the diagnosis and treatment of ALS have been hampered by lack of effective biomarkers. A diagnostic biomarker for ALS would enable prompt initiation of neuroprotective therapy, ideally when neural structures were intact and disease severity remained mild. Furthermore, a biomarker capable of monitoring disease progression may facilitate conduct of future clinical trials, by reducing sample size and trial duration. As such, the present review summarizes pathophysiology, diagnosis and treatment of ALS, with a focus on the development of effective biomarkers.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalClinical Investigation
  • SubjectGeneral & Internal Medicine
  • BylineArticles whose byline prints “Benjamin Chee Chuan Cheah”
  • BylineArticles whose byline prints “Steve Vucic”
  • BylineArticles whose byline prints “Matthew Colm Kiernan”